PR
DNLI icon

PSP Research’s Denali Therapeutics DNLI Stock Holding History

PSP Research’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Buy
+8,463
New +$174K 0.12% 66
2026
Q1 		– Sell
-31,762
Closed -$524K – 88
2025
Q4 		$524K Buy
+31,762
New +$536K 0.46% 57

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PSP Research's DNLI Position: Q2 2026 in Review

PSP Research opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 8,463 shares worth $218K. The stake represents 0.12% of the portfolio and ranks #66 among its holdings. This is a return to the name: PSP Research previously reported a position in DNLI as recently as Q4 2025.

PSP Research first reported a position in DNLI in Q4 2025 and has held it in 2 quarters since. The position peaked at $524K in Q4 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • PSP Research held 8,463 shares of Denali Therapeutics worth $218K as of Q2 2026.
  • Denali Therapeutics was a new PSP Research position in Q2 2026.
  • Denali Therapeutics made up 0.12% of PSP Research's portfolio in Q2 2026, its #66 holding.
  • PSP Research first reported a position in Denali Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • PSP Research's Denali Therapeutics position peaked at $524K in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.